Stefania Capone
YOU?
Author Swipe
View article: Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates
Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates Open
Summary SARS-CoV-2 continues to pose a global threat, and current vaccines, while effective against severe illness, fall short in preventing transmission. To address this challenge, there’s a need for vaccines that induce mucosal immunity …
View article: E-239 Role of embolization in head and neck cancer: review of indications and current practice
E-239 Role of embolization in head and neck cancer: review of indications and current practice Open
Introduction Head and neck tumors can provide challenging pathologies given their location in relation to essential structures, their potential for hypervascularity, and difficulty in management of recurrent or advanced cancer. Here we rev…
View article: Corrigendum: Improved memory CD8 T cell response to delayed vaccine boost is associated with a distinct molecular signature
Corrigendum: Improved memory CD8 T cell response to delayed vaccine boost is associated with a distinct molecular signature Open
[This corrects the article DOI: 10.3389/fimmu.2023.1043631.].
View article: Improved memory CD8 T cell response to delayed vaccine boost is associated with a distinct molecular signature
Improved memory CD8 T cell response to delayed vaccine boost is associated with a distinct molecular signature Open
Effective secondary response to antigen is a hallmark of immunological memory. However, the extent of memory CD8 T cell response to secondary boost varies at different times after a primary response. Considering the central role of memory …
View article: Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults Open
Cohorts of healthy younger adults (18–50yrs) and healthy older adults (60–75yrs) were immunized intramuscularly or intranasally with an adenovirus-vectored RSV vaccine (PanAd3-RSV) as a prime dose and boosted with PanAd3-RSV or a poxvirus-…
View article: GRAd-COV2 vaccine provides potent and durable immunity in randomised placebo-controlled phase 2 trial (COVITAR)
GRAd-COV2 vaccine provides potent and durable immunity in randomised placebo-controlled phase 2 trial (COVITAR) Open
Background SARS-CoV-2 ongoing pandemic and heterologous immunization approaches implemented worldwide for booster doses call for diversified vaccines portfolio. We report safety and immunogenicity of GRAd-COV2, a novel gorilla adenovirus-b…
View article: Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results Open
Despite the successful deployment of efficacious vaccines and therapeutics, the development of novel vaccines for SARS-CoV-2 remains a major goal to increase vaccine doses availability and accessibility for lower income setting. We report …
View article: Improved memory CD8 T cell response to delayed vaccine boost is associated with a distinct molecular signature
Improved memory CD8 T cell response to delayed vaccine boost is associated with a distinct molecular signature Open
Summary Although the prime/boost interval can impact vaccine responses, the criteria for deciding its time length are poorly defined. To address this, we examined CD8 T cell responsiveness to boost in a BALB/c mouse model of intramuscular …
View article: Adenovirus vectors activate Vδ2 <sup>+</sup> γδT cells in a type I interferon‐, TNF‐, and IL‐18‐dependent manner
Adenovirus vectors activate Vδ2 <sup>+</sup> γδT cells in a type I interferon‐, TNF‐, and IL‐18‐dependent manner Open
Vδ2+ γδT cells are unconventional T cells that can be activated by cytokines without TCR signaling. Adenovirus vaccine vectors activated Vδ2+ γδT cells in an interleukin 18-, TNF-, and type I interferon-dependent manner. This stimulatory c…
View article: 410 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI)
410 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI) Open
Background Defective DNA mismatch repair (dMMR) leads to high levels of microsatellite-instability (MSI-H) and insertions or deletions in coding regions, resulting in the generation of tumor-specific frameshift peptides (FSPs). We selected…
View article: GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults Open
GRAd-COV2, a candidate vaccine for COVID-19 based on a gorilla adenovirus, is safe and immunogenic in younger and older adults.
View article: Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19 Open
Here we report on the humoral and cellular immune response in eight volunteers who autonomously chose to adhere to the Italian national COVID-19 vaccination campaign more than 3 months after receiving a single administration GRAd-COV2 vacc…
View article: Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 Open
The coronavirus disease 2019 (COVID-19) pandemic caused by the emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health, and there is an urgent need to develop safe and effective vaccines. Here, …
View article: GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults
GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults Open
Safe and effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed to control the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those…
View article: Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C
Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C Open
[This corrects the article DOI: 10.1371/journal.pntd.0008459.].
View article: Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection
Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection Open
BackgroundA safe and effective vaccine to prevent chronic hepatitis C virus (HCV) infection is a critical component of efforts to eliminate the disease.MethodsIn this phase 1-2 randomized, double-blind, placebo-controlled trial, we evaluat…
View article: MAIT cell activation augments adenovirus vector vaccine immunogenicity
MAIT cell activation augments adenovirus vector vaccine immunogenicity Open
Vaccines get a help-MAIT Mucosal-associated invariant T (MAIT) cells are a T cell subset important for mucosal homeostasis. These cells recognize derivatives of microbiota-derived vitamin B2 precursors but can also be activated by certain …
View article: A DNA/Ki67-Based Flow Cytometry Assay for Cell Cycle Analysis of Antigen-Specific CD8 T Cells in Vaccinated Mice
A DNA/Ki67-Based Flow Cytometry Assay for Cell Cycle Analysis of Antigen-Specific CD8 T Cells in Vaccinated Mice Open
The cell cycle of antigen-specific T cells in vivo has been examined by using a few methods, all of which possess some limitations. Bromodeoxyuridine (BrdU) marks cells that are in or recently completed S-phase, and carboxyfluorescein succ…
View article: Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys
Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys Open
Replication-deficient chimpanzee adenovirus (ChAd) vectors represent an attractive vaccine platform and are thus employed as vaccine candidates against several infectious diseases. Since inducing effective immunity depends on the interplay…
View article: Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 Open
The COVID-19 pandemic caused by the emergent SARS-CoV-2 coronavirus threatens global public health and there is an urgent need to develop safe and effective vaccines. Here we report the generation and the preclinical evaluation of a novel …
View article: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C
A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C Open
Rabies, caused by RNA viruses in the Genus Lyssavirus, is the most fatal of all infectious diseases. This neglected zoonosis remains a major public health problem in developing countries, causing the death of an estimated 25,000-159,000 pe…
View article: MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans
MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans Open
Administration of an MHC class II invariant chain–adjuvanted HCV vaccine in humans leads to enhanced immunogenicity via the proteasome pathway.
View article: Characterizing Hepatitis C Virus–Specific CD4+ T Cells Following Viral‐Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure
Characterizing Hepatitis C Virus–Specific CD4+ T Cells Following Viral‐Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure Open
Background and Aims Induction of functional helper CD4 + T cells is the hallmark of a protective immune response against hepatitis C virus (HCV), associated with spontaneous viral clearance. Heterologous prime/boost viral vectored vaccinat…
View article: LB10. A Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Vaccine to Prevent Chronic Hepatitis C Virus Infection in an at-Risk Population
LB10. A Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Vaccine to Prevent Chronic Hepatitis C Virus Infection in an at-Risk Population Open
Background The development of a safe and effective vaccine to prevent chronic hepatitis C virus (HCV) infection is a critical component of elimination efforts, providing the rationale for the first HCV vaccine efficacy trial. Methods In a …
View article: Activation of MAIT cells plays a critical role in viral vector vaccine immunogenicity
Activation of MAIT cells plays a critical role in viral vector vaccine immunogenicity Open
Mucosal-associated invariant T (MAIT) cells can be activated by viruses through a cytokine-dependent mechanism, and thereby protect from lethal infection. Given this, we reasoned MAIT cells may have a critical role in the immunogenicity of…